ARTCLINE

ARTCLINE GmbH develops a novel immune cell-based extracorporeal sepsis therapy. Their ARTICE® therapy uses immune cells from healthy donors to assist and reactivate the patient's immune system in cases of septic shock. This aims to address the significant challenge of sepsis in healthcare systems worldwide.

Buy Funded Startups lists

Funding Round:

Funding Amount: €4.4M

Date: 25-Mar-2024

Investors: family offices from Germany

Markets: Healthtech, Biotechnology Research, Medical

HQ: Rostock, Mecklenburg-Vorpommern, Germany

Founded: 2007

Website: https://www.artcline.de/

LinkedIn: https://www.linkedin.com/company/artcline

Twitter: https://twitter.com/ARTCLINE_

Instagram: